JP7423520B2 - Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法 - Google Patents

Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法 Download PDF

Info

Publication number
JP7423520B2
JP7423520B2 JP2020526198A JP2020526198A JP7423520B2 JP 7423520 B2 JP7423520 B2 JP 7423520B2 JP 2020526198 A JP2020526198 A JP 2020526198A JP 2020526198 A JP2020526198 A JP 2020526198A JP 7423520 B2 JP7423520 B2 JP 7423520B2
Authority
JP
Japan
Prior art keywords
cas9
sequence
polynucleotide
endonuclease
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526198A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503279A (ja
Inventor
マルチェッロ・マレスカ
アミル・タヘリ－ガーファロキ
フレデリク・カールソン
モハマド・ボールーリー－イェガネー
ロレンツ・マルティン・マイヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2021503279A publication Critical patent/JP2021503279A/ja
Priority to JP2024005210A priority Critical patent/JP7703707B2/ja
Application granted granted Critical
Publication of JP7423520B2 publication Critical patent/JP7423520B2/ja
Priority to JP2025065457A priority patent/JP2025121906A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/301—Endonuclease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020526198A 2017-11-16 2018-11-16 Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法 Active JP7423520B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024005210A JP7703707B2 (ja) 2017-11-16 2024-01-17 Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
JP2025065457A JP2025121906A (ja) 2017-11-16 2025-04-11 Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762587029P 2017-11-16 2017-11-16
US62/587,029 2017-11-16
US201862693690P 2018-07-03 2018-07-03
US62/693,690 2018-07-03
PCT/US2018/061680 WO2019099943A1 (en) 2017-11-16 2018-11-16 Compositions and methods for improving the efficacy of cas9-based knock-in strategies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024005210A Division JP7703707B2 (ja) 2017-11-16 2024-01-17 Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2021503279A JP2021503279A (ja) 2021-02-12
JP7423520B2 true JP7423520B2 (ja) 2024-01-29

Family

ID=64870555

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526198A Active JP7423520B2 (ja) 2017-11-16 2018-11-16 Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
JP2024005210A Active JP7703707B2 (ja) 2017-11-16 2024-01-17 Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
JP2025065457A Pending JP2025121906A (ja) 2017-11-16 2025-04-11 Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024005210A Active JP7703707B2 (ja) 2017-11-16 2024-01-17 Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
JP2025065457A Pending JP2025121906A (ja) 2017-11-16 2025-04-11 Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法

Country Status (5)

Country Link
US (2) US20210180059A1 (https=)
EP (1) EP3710583A1 (https=)
JP (3) JP7423520B2 (https=)
CN (2) CN120310773A (https=)
WO (1) WO2019099943A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637739B2 (en) * 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
JP7229923B2 (ja) 2017-01-06 2023-02-28 エディタス・メディシン、インコーポレイテッド ヌクレアーゼ切断を評価する方法
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
MX2019014640A (es) 2017-06-09 2020-10-05 Editas Medicine Inc Nucleasas de repeticiones palíndromicas agrupadas y regularmente interespaciadas de proteina asociada 9 (cas9) genomanipuladas.
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US11530425B2 (en) 2019-10-09 2022-12-20 Massachusetts Institute Of Technology Systems, methods, and compositions for correction of frameshift mutations
EP4133069A2 (en) 2020-04-08 2023-02-15 Astrazeneca AB Compositions and methods for improved site-specific modification
CN116209751A (zh) * 2020-07-07 2023-06-02 北京奥源和力生物技术有限公司 用于hsv-1基因编辑的指导rna及其方法
CN114438235A (zh) * 2020-11-04 2022-05-06 深圳市南山区疾病预防控制中心 一种同时检测嗜低温弓形杆菌及斯氏弓形杆菌的引物探针组件、试剂盒及其应用
WO2022214522A2 (en) 2021-04-07 2022-10-13 Astrazeneca Ab Compositions and methods for site-specific modification
US20240384246A1 (en) 2021-05-27 2024-11-21 Astrazeneca Ab Ca s9 effector proteins with enhanced stability
CN113481184A (zh) * 2021-08-06 2021-10-08 北京大学 融合蛋白以及其使用方法
WO2023052508A2 (en) 2021-09-30 2023-04-06 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
WO2023109849A1 (en) * 2021-12-15 2023-06-22 Wuhan University Dna polymerase-mediated genome editing
EP4689155A1 (en) 2023-03-29 2026-02-11 Astrazeneca AB Use of inhibitors to increase efficiency of crispr/cas insertions
CN119614679A (zh) * 2023-09-14 2025-03-14 厦门大学 一款通用型核酸检测平台
CN116949012B (zh) * 2023-09-20 2024-01-02 广州瑞风生物科技有限公司 一种融合蛋白及其应用
EP4678742A1 (en) 2024-07-10 2026-01-14 Astrazeneca AB Improved cas9 proteins
WO2026083309A1 (en) 2024-10-17 2026-04-23 Astrazeneca Ab Use of inhibitors or modulators of artemis in gene editing

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016502840A (ja) 2012-12-06 2016-02-01 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ Ｃｒｉｓｐｒに基づくゲノム修飾および制御
WO2016080795A1 (ko) 2014-11-19 2016-05-26 기초과학연구원 두 개의 벡터로부터 발현된 cas9 단백질을 이용한 유전자 발현 조절 방법
JP2016517276A (ja) 2013-03-15 2016-06-16 ザ ジェネラル ホスピタル コーポレイション ＲＮＡ誘導型ＦｏｋＩヌクレアーゼ（ＲＦＮ）を用いたＲＮＡ誘導型ゲノム編集の特異性の増大
JP2016521994A (ja) 2013-06-17 2016-07-28 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
WO2017189308A1 (en) 2016-04-19 2017-11-02 The Broad Institute Inc. Novel crispr enzymes and systems
JP2017532001A (ja) 2013-12-12 2017-11-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5895309A (en) 1998-02-09 1999-04-20 Spector; Donald Collapsible hula-hoop
JP2008078613A (ja) 2006-08-24 2008-04-03 Rohm Co Ltd 窒化物半導体の製造方法及び窒化物半導体素子
EP3269395A1 (en) 2008-11-07 2018-01-17 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
EP2691443B1 (en) 2011-03-28 2021-02-17 Massachusetts Institute of Technology Conjugated lipomers and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
AU2013293270B2 (en) 2012-07-25 2018-08-16 Massachusetts Institute Of Technology Inducible DNA binding proteins and genome perturbation tools and applications thereof
WO2014033644A2 (en) 2012-08-28 2014-03-06 Novartis Ag Methods of nuclease-based genetic engineering
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
IL239344B2 (en) * 2012-12-12 2024-06-01 Broad Inst Inc Systems engineering, methods and optimal guiding components for sequence manipulation
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
CA2913234A1 (en) 2013-05-22 2014-11-27 Northwestern University Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
SG10201804975PA (en) * 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
EP3470089A1 (en) * 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2015089364A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
SG11201701245QA (en) * 2014-08-27 2017-03-30 Caribou Biosciences Inc Methods for increasing cas9-mediated engineering efficiency
WO2016106236A1 (en) * 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
US9650617B2 (en) 2015-01-28 2017-05-16 Pioneer Hi-Bred International. Inc. CRISPR hybrid DNA/RNA polynucleotides and methods of use
WO2016196655A1 (en) * 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
US20180201912A1 (en) * 2015-07-14 2018-07-19 The University Of Tokyo Modified fncas9 protein and use thereof
JP7044373B2 (ja) * 2015-07-15 2022-03-30 ラトガース，ザ ステート ユニバーシティ オブ ニュージャージー ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
WO2017151444A1 (en) * 2016-02-29 2017-09-08 Agilent Technologies, Inc. Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
EP3426778A1 (en) * 2016-03-11 2019-01-16 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
EP3426780A1 (en) * 2016-03-11 2019-01-16 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2017189336A1 (en) * 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing
US20190136230A1 (en) * 2016-05-06 2019-05-09 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016502840A (ja) 2012-12-06 2016-02-01 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ Ｃｒｉｓｐｒに基づくゲノム修飾および制御
JP2016517276A (ja) 2013-03-15 2016-06-16 ザ ジェネラル ホスピタル コーポレイション ＲＮＡ誘導型ＦｏｋＩヌクレアーゼ（ＲＦＮ）を用いたＲＮＡ誘導型ゲノム編集の特異性の増大
JP2016521994A (ja) 2013-06-17 2016-07-28 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
JP2017532001A (ja) 2013-12-12 2017-11-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
WO2016080795A1 (ko) 2014-11-19 2016-05-26 기초과학연구원 두 개의 벡터로부터 발현된 cas9 단백질을 이용한 유전자 발현 조절 방법
WO2017189308A1 (en) 2016-04-19 2017-11-02 The Broad Institute Inc. Novel crispr enzymes and systems

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Scientific Reports，2016年，Vol.6:37584，pp.1-9

Also Published As

Publication number Publication date
JP2024050637A (ja) 2024-04-10
JP2025121906A (ja) 2025-08-20
US20250034562A1 (en) 2025-01-30
US20210180059A1 (en) 2021-06-17
CN111448313A (zh) 2020-07-24
CN120310773A (zh) 2025-07-15
JP7703707B2 (ja) 2025-07-07
EP3710583A1 (en) 2020-09-23
JP2021503279A (ja) 2021-02-12
WO2019099943A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
JP7423520B2 (ja) Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
US20240200044A1 (en) Evolution of talens
JP6737974B1 (ja) ヌクレアーゼ媒介ｄｎａアセンブリ
US10913941B2 (en) Enzymes with RuvC domains
JP7201153B2 (ja) プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
CN102124112B (zh) 基于同源重组dna的克隆方法及组合物
CN106795521B (zh) 用于修饰所靶向基因座的方法和组合物
US20180195089A1 (en) CRISPR Oligonucleotides and Gene Editing
JP2023522848A (ja) 改善された部位特異的改変のための組成物及び方法
CA3111432A1 (en) Novel crispr enzymes and systems
WO2016205745A2 (en) Cell sorting
CN112301024A (zh) 使用RNA引导的FokI核酸酶(RFN)提高RNA引导的基因组编辑的特异性
US20200255867A1 (en) Double selection hdr crispr-based editing
US12188044B2 (en) Methods for genomic integration for Kluyveromyces host cells
US20230212612A1 (en) Genome editing system and method
AU2017302657A1 (en) Mice comprising mutations resulting in expression of c-truncated fibrillin-1
JP2024518793A (ja) 向上した安定性を有するｃａｓ９エフェクタータンパク質
JP2024501892A (ja) 新規の核酸誘導型ヌクレアーゼ
US20250122535A1 (en) Crispr-associated transposases and methods of use thereof
CN113795588B (zh) 用于在靶向性载体中无瘢痕引入靶向修饰的方法
Penewit et al. Recombineering in Staphylococcus aureus
WO2014013127A1 (en) Method for producing hyperactive transposase mutants

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240117

R150 Certificate of patent or registration of utility model

Ref document number: 7423520

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150